| 101 |
NCT00250679 |
Completed
Has Results |
Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease |
- Chronic Obstructive Pulmonary Disease
- Bronchitis
- Emphysema
|
- Drug: Arformoterol tartrate inhalation solution
- Drug: Arformoterol 25 ųg BID
- Drug: Formoterol 12 ųg BID
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Percent (%) of Participants With Adverse Events (AEs), in Particular COPD Exacerbations
- Number of Participants With New 24-Hour Holter Monitoring Alerts
- Number of Participants With Potentially Clinically Significant Glucose Evaluations
- (and 28 more...)
|
443 |
All |
35 Years and older (Adult, Senior) |
NCT00250679 |
091-061 |
|
October 2005 |
October 2007 |
October 2007 |
November 8, 2005 |
June 4, 2012 |
February 19, 2009 |
- Birmingham, Alabama, United States
- Jasper, Alabama, United States
- Mobile, Alabama, United States
- (and 57 more...)
|
| 102 |
NCT00232908 |
Completed |
QUALITE Study - A Study of Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With Human Immunodeficiency Virus-1 (HIV-1) Infection |
|
- Drug: ARV regimen
- Drug: enfuvirtide [Fuzeon]
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- QoL (MOS-HIV)\n
- Change from baseline in HIV-RNA
- Change from baseline in CD4 count
|
361 |
All |
16 Years and older (Child, Adult, Senior) |
NCT00232908 |
ML18018 |
|
June 2004 |
October 2005 |
October 2005 |
October 5, 2005 |
November 2, 2016 |
|
- Phoenix, Arizona, United States
- Bakersfield, California, United States
- Berkeley, California, United States
- (and 103 more...)
|
| 103 |
NCT00227318 |
Completed |
TROPHY - Candesartan Cilexetil Long-term Hypertension Prevention Trial |
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Masking: Double
- Primary Purpose: Prevention
|
- To determine whether candesartan cilexetil 16 mg compared to placebo reduces the crude incidence of hypertension in a population with high normal BP evaluated after a 4-year study period consisting of 2 years of double-blind treatment followed by 2 years
- To evaluate the reduction in BP after 2 years treatment with candesartan cilexetil 16 mg vs placebo in patients with high normal BP.
- To evaluate the incidence of hypertension after 2 years treatment with candesartan cilexetil 16 mg vs placebo in patients with high normal BP.
- To evaluate Health-related Quality of Life yearly during 2 years treatment with candesartan cilexetil 16mg vs placebo and yearly during a 2-year follow up period in patients with high normal BP.
|
1000 |
All |
30 Years to 65 Years (Adult) |
NCT00227318 |
SH-AHM-0030
D2455L00010 |
|
July 1998 |
October 2005 |
October 2005 |
September 28, 2005 |
August 30, 2011 |
|
- Research Site
Mobile, Alabama, United States - Research Site
Long Beach, California, United States - Research Site
Redondo Beach, California, United States - (and 39 more...)
|
| 104 |
NCT00225277 |
Completed
Has Results |
Efficacy Study of Pioglitazone Compared to Glimepiride on Coronary Atherosclerotic Disease Progression in Subjects With Type 2 Diabetes Mellitus |
|
- Drug: Pioglitazone
- Drug: Glimepiride
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Nominal Change From Baseline in Percent Atheroma Volume
- Nominal Change From Baseline in Normalized Total Atheroma Volume
- Number of Subjects Experiencing Any of the Composite Endpoint A Cardiovascular Events
- (and 2 more...)
|
547 |
All |
35 Years to 85 Years (Adult, Senior) |
NCT00225277 |
01-01-TL-OPI-516
U1111-1114-0400 |
PERISCOPE |
July 2003 |
October 2007 |
October 2007 |
September 23, 2005 |
February 28, 2012 |
June 10, 2009 |
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Huntington Beach, California, United States
- (and 76 more...)
|
| 105 |
NCT00216190 |
Completed |
A Safety and Efficacy Study of Dexmedetomidine in ICU Patients Requiring Continuous Sedation |
- Mechanically Ventilated and Intubated Subjects
|
- Drug: Dexmedetomidine HCL Injection
- Drug: Midazolam Injection
|
Interventional |
Phase 4 |
- Hospira, now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The percentage of time spent within the protocol specified sedation range (Richmond Agitation-Sedation Scale [RASS] range of -2 to +1)
- Percentage of subjects able to achieve a RASS between - 2 and +1 without interruption of study drug
- Percentage of subjects with evidence of delirium (Confusion Assessment Method [CAM]-ICU positive) while on study drug
- (and 7 more...)
|
420 |
All |
18 Years and older (Adult, Senior) |
NCT00216190 |
2001-001 |
|
March 2005 |
|
August 2007 |
September 22, 2005 |
July 23, 2015 |
|
- Birmingham, Alabama, United States
- Chandler, Arizona, United States
- Phoenix, Arizona, United States
- (and 93 more...)
|
| 106 |
NCT00215449 |
Completed |
Study in Patients With COPD |
|
- Drug: Formoterol Fumarate
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Measure of lung function
- Change in lung function, as well as vital signs
- Physical Exam results, Adverse Event reporting, etc
|
690 |
All |
40 Years and older (Adult, Senior) |
NCT00215449 |
DL-059 |
|
|
December 2005 |
April 2006 |
September 22, 2005 |
November 11, 2010 |
|
- Research Site
Bessemer, Alabama, United States - Research Site
Birmingham, Alabama, United States - Research Site
Phoenix, Arizona, United States - (and 65 more...)
|
| 107 |
NCT00206167 |
Completed |
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD |
- Chronic Obstructive Pulmonary Disease
|
- Drug: Budesonide/formoterol pMDI
- Drug: Formoterol Turbuhaler
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Pre-dose and 1-hour post-dose FEV1 over the 12 months treatment period
- Patient-reported outcome variables regarding disease status (incl. PEF), collected via questionnaires and diaries
- Health care utilization
- (and 2 more...)
|
1600 |
All |
40 Years and older (Adult, Senior) |
NCT00206167 |
D5899C00001
EurodraCT No: 2004-001 168-28
SUN |
|
April 2005 |
|
September 2007 |
September 21, 2005 |
March 27, 2009 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Huntsville, Alabama, United States - Research Site
Jasper, Alabama, United States - (and 213 more...)
|
| 108 |
NCT00206154 |
Completed |
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients |
- Chronic Obstructive Pulmonary Disease
|
- Drug: Budesonide/formoterol pMDI
- Drug: Budesonide pMDI
- Drug: Formoterol Turbuhaler
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Pre-dose and 1-hour post-dose FEV1 over the 6 months treatment period
- Patient-reported outcome variables regarding disease status (incl. PEF), collected via questionnaires and diaries
- Health care utilization
- (and 3 more...)
|
1500 |
All |
40 Years and older (Adult, Senior) |
NCT00206154 |
D5899C00002
EurodraCT No: 2004-001183-41 |
|
April 2005 |
|
December 2006 |
September 21, 2005 |
March 27, 2009 |
|
- Research Site
Birmingham, Alabama, United States - Research Site
Jasper, Alabama, United States - Research Site
Mobile, Alabama, United States - (and 212 more...)
|
| 109 |
NCT00153062 |
Completed
Has Results |
PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes |
|
- Drug: Aggrenox
- Drug: Clopidogrel placebo
- Drug: Micardis
- (and 3 more...)
|
Interventional |
Phase 4 |
- Boehringer Ingelheim
- GlaxoSmithKline
- Bayer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)
- Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)
- Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)
- (and 2 more...)
|
20332 |
All |
50 Years and older (Adult, Senior) |
NCT00153062 |
9.159 |
|
August 2003 |
April 2008 |
|
September 12, 2005 |
May 13, 2014 |
September 2, 2009 |
- 9.159.1101 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States - 9.159.1173 Boehringer Ingelheim Investigational Site
Huntsville, Alabama, United States - 9.159.1058 Boehringer Ingelheim Investigational Site
Mobile, Alabama, United States - (and 664 more...)
|
| 110 |
NCT00144339 |
Completed
Has Results |
Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: tiotropium
- Drug: placebo
|
Interventional |
Phase 3 |
|
Industry |
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
|
- Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
- Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 Years
- Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 1 to 30 Days After Completion of Double Blinded Treatment
- (and 84 more...)
|
5993 |
All |
40 Years and older (Adult, Senior) |
NCT00144339 |
205.235 |
|
December 2002 |
February 2008 |
|
September 5, 2005 |
May 20, 2014 |
August 17, 2009 |
- 205.235.3779 Boehringer Ingelheim Investigational Site
Anniston, Alabama, United States - 205.235.3785 Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States - 205.235.3804 Boehringer Ingelheim Investigational Site
Jasper, Alabama, United States - (and 487 more...)
|
| 111 |
NCT00143611 |
Completed |
Efficacy & Safety of Resatorvid in Adults With Severe Sepsis |
|
- Drug: Resatorvid
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- 28-day All-cause Mortality.
- Change from Baseline in Organ Failure Assessment
- Mean Systemic Inflammatory Response
- (and 4 more...)
|
277 |
All |
18 Years and older (Adult, Senior) |
NCT00143611 |
01-04-TL-242-011
2005-003561-16
U1111-1127-5919
DOH-27-0406-1213 |
|
September 2005 |
February 2007 |
February 2007 |
September 2, 2005 |
February 2, 2012 |
|
- Birmingham, Alabama, United States
- Mobile, Alabama, United States
- Phoenix, Arizona, United States
- (and 142 more...)
|
| 112 |
NCT00106509 |
Completed |
A Study of GT267-004 Versus Vancomycin and GT267-004 Versus Metronidazole in Patients With C.Difficile - Associated Diarrhea |
- Clostridium Enterocolitis
- Pseudomembranous Colitis
|
- Drug: tolevamer potassium-sodium (GT267-004)
|
Interventional |
Phase 3 |
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Resolution of diarrhea
- Time to resolution of diarrhea
- Recurrence rate
- (and 3 more...)
|
520 |
All |
18 Years and older (Adult, Senior) |
NCT00106509 |
GD3-170-301 |
|
March 2005 |
|
February 2007 |
March 28, 2005 |
March 5, 2015 |
|
- Phoenix, Arizona, United States
- Phoenix, Arizona, United States
- Rogers, Arkansas, United States
- (and 137 more...)
|
| 113 |
NCT00105144 |
Completed |
Study of Micafungin in Patients With Invasive Candidiasis or Candidemia |
|
- Drug: Micafungin
- Drug: Caspofungin
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Overall treatment success, based on the investigator's assessment of pre-defined clinical and mycological response at the End of intravenous (IV) Therapy
- Overall treatment success, based on the Data Review Panel's assessment of pre-defined clinical and mycological response at the End of IV Therapy
|
611 |
All |
18 Years and older (Adult, Senior) |
NCT00105144 |
03-0-192 |
|
September 2004 |
April 2006 |
April 2006 |
March 8, 2005 |
September 18, 2014 |
|
- Birmingham, Alabama, United States
- Little Rock, Arkansas, United States
- Los Angeles, California, United States
- (and 164 more...)
|
| 114 |
NCT00097357 |
Completed |
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery |
- Venous Thrombosis
- Pulmonary Embolism
|
- Drug: Apixaban
- Drug: Enoxaparin
- Drug: Warfarin
- (and 2 more...)
|
Interventional |
Phase 2
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Determine the dose-response relationship among the 3 QD and 3 BID doses of BMS-562247 on the composite endpoint of adjudicated VTE events and all-cause death in subjects treated with study medication for 12 +/-2 days following surgery
- Assess the effect of QD and BID dose of BMS-562247 vs subcutaneous 30 mg q12h enoxaparin and warfarin on the composite endpoint of adjudication VTE events and all-cause death in subjects treated for 12 +/-2 days following surgery
- Assess the effect of each QD and BID dose of BMS-562247 versus subcutaneous 30 mg q12h enoxaparin and oral warfarin on the incidence of adjudicated major bleeding events in subjects treated with study medication for 12 +/-2 days following surgery
- (and 2 more...)
|
1238 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT00097357 |
CV185-010 |
|
October 2004 |
December 2005 |
December 2005 |
November 23, 2004 |
March 2, 2010 |
|
- Local Institution
Birmingham, Alabama, United States - Local Institution
Mobile, Alabama, United States - Local Institution
Northport, Alabama, United States - (and 145 more...)
|
| 115 |
NCT00090103 |
Completed
Has Results |
Benign Prostatic Hyperplasia Trial With Dutasteride And Tamsulosin Combination Treatment |
|
- Drug: dutasteride 0.5mg once daily for 4 years
- Drug: tamsulosin 0.4mg once daily for 4 years
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Number of Events of Acute Urinary Retention (AUR) or Benign Prostatic Hyperplasia (BPH)-Related Prostatic Surgery at the Indicated Time Periods.
- Number of Participants With AUR or BPH-related Surgery
- Number of Events of First BPH Clinical Progression at Years 1, 2, 3 and 4
- (and 28 more...)
|
4844 |
Male |
50 Years and older (Adult, Senior) |
NCT00090103 |
ARI40005 |
|
November 2003 |
April 2009 |
April 2009 |
August 26, 2004 |
February 28, 2017 |
March 16, 2010 |
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - (and 501 more...)
|
| 116 |
NCT00089986 |
Completed
Has Results |
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults |
|
- Drug: Intravenous GR270773- Phospholipid Emulsion
- Other: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
|
- Percentage of Participants With 28-Day All Cause Mortality
- Number of Participants With New Onset Organ Failure, Regardless of Cause, Occurring During the 28 Days Post Enrollment in an Organ Not in Failure at Enrolment
- Number of Participants With New Onset Organ Failure of Respiratory Failure, Cardiovascular Failure, Renal Failure and Coagulopathy, Regardless of Cause, Occurring During the 28 Days Post Enrollment in an Organ Not in Failure at Enrollment
- Assessment of Safety/Tolerability by Determining the Number of Participants With Any Adverse Events (AE), Serious Adverse Events (SAE) and Fatal SAE
|
1415 |
All |
18 Years and older (Adult, Senior) |
NCT00089986 |
EMD20001 |
|
September 1, 2004 |
April 1, 2007 |
April 15, 2007 |
August 23, 2004 |
August 21, 2017 |
May 4, 2017 |
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Phoenix, Arizona, United States - GSK Investigational Site
Tucson, Arizona, United States - (and 387 more...)
|
| 117 |
NCT00002290 |
Completed |
The Safety and Effectiveness of Zidovudine Plus Acyclovir in Patients With Early HIV Infection |
|
- Drug: Zidovudine
- Drug: Acyclovir
|
Interventional |
Not Applicable |
- Glaxo Wellcome
- NIH AIDS Clinical Trials Information Service
|
Industry |
- Masking: Double
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00002290 |
018A
03 |
|
|
|
|
August 31, 2001 |
June 24, 2005 |
|
- Birmingham Veterans Administration Med Ctr / Univ of Alabama
Birmingham, Alabama, United States - Univ of Arizona / Health Science Ctr
Tucson, Arizona, United States - ViRx Inc
San Francisco, California, United States - (and 11 more...)
|
| 118 |
NCT00084071 |
Completed |
Tifacogin for the Treatment of Patients With Severe Community-Acquired Pneumonia |
|
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Compare the effect of tifacogin vs placebo administration.
|
2136 |
All |
Child, Adult, Senior |
NCT00084071 |
CTFP561A2308 |
|
May 2004 |
July 2008 |
July 2008 |
June 8, 2004 |
July 13, 2012 |
|
- Mobile, Alabama, United States
- Loma Linda, California, United States
- Los Angeles, California, United States
- (and 147 more...)
|
| 119 |
NCT00080496 |
Completed |
Study Evaluating Tigecycline Versus Imipenem/Cilastatin in Hospital-Acquired Pneumonia |
|
- Drug: Tigecycline
- Drug: Imipenem
- Drug: Cilastatin
|
Interventional |
Phase 3 |
- Wyeth is now a wholly owned subsidiary of Pfizer
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The co-primary efficacy endpoints are clinical response at the TOC assessment for the clinically evaluable population and the clinical modified intent-to-treat population.
|
430 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00080496 |
3074A1-311 |
|
July 2003 |
|
December 2006 |
April 7, 2004 |
August 4, 2008 |
|
- Phoenix, Arizona, United States
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- (and 26 more...)
|
| 120 |
NCT00046345 |
No longer available |
Atazanavir for HIV Infected Individuals: An Early Access Program |
|
- Drug: Atazanavir (BMS-232632)
|
Expanded Access |
|
|
Industry |
|
|
|
All |
16 Years and older (Child, Adult, Senior) |
NCT00046345 |
AI424-900 |
|
May 2002 |
|
July 2003 |
September 30, 2002 |
April 14, 2011 |
|
- Local Institution
Hobson City, Alabama, United States - Local Institution
Anchorage, Alaska, United States - Local Institution
Phoenix, Arizona, United States - (and 162 more...)
|
| 121 |
NCT00036062 |
Completed |
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects With Acute Lung Injury |
- Respiratory Distress Syndrome, Adult
- Acute Lung Injury
|
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
600 |
All |
18 Years and older (Adult, Senior) |
NCT00036062 |
6025
H6W-MC-MCAA |
|
August 2001 |
|
December 2002 |
May 8, 2002 |
July 19, 2006 |
|
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- (and 107 more...)
|
| 122 |
NCT00034294 |
Completed |
A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea |
- Clostridium Difficile-Associated Diarrhea
- Clostridium Enterocolitis
- Clostridium Difficile Diarrhea
- (and 2 more...)
|
|
Interventional |
Phase 2 |
- Genzyme, a Sanofi Company
- Sanofi
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
|
300 |
All |
18 Years and older (Adult, Senior) |
NCT00034294 |
GTC-80-203
GT1105 |
|
February 2002 |
|
July 2003 |
April 25, 2002 |
March 5, 2015 |
|
- Mobile, Alabama, United States
- Phoenix, Arizona, United States
- Tucson, Arizona, United States
- (and 96 more...)
|
| 123 |
NCT00041639 |
Completed |
Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer |
|
- Drug: hMN14 (labetuzumab)
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
75 |
All |
18 Years and older (Adult, Senior) |
NCT00041639 |
IM-T-hMN14-03 |
|
January 2000 |
|
December 2003 |
July 15, 2002 |
June 24, 2005 |
|
- Hoag Cancer Center
Newport Beach, California, United States - Washington Hospital Center
Washington, District of Columbia, United States - Bay Pines VA Medical Center
St. Petersburg, Florida, United States - (and 7 more...)
|
| 124 |
NCT00040599 |
Completed |
Safety Study of 90Y-hMN14 to Treat Colorectal Cancer |
- Colorectal Cancer
- Colon Cancer
- Rectal Cancer
- (and 3 more...)
|
- Drug: hMN14 (labetuzumab)
|
Interventional |
Phase 1
Phase 2 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
72 |
All |
18 Years and older (Adult, Senior) |
NCT00040599 |
IM-T-hMN14-02 |
|
January 2000 |
|
January 2004 |
July 3, 2002 |
January 9, 2008 |
|
- Hoag Cancer Center
Newport Beach, California, United States - Washington Hospital Center
Washington, District of Columbia, United States - Bay Pines VA Medical Center
St. Petersburg, Florida, United States - (and 7 more...)
|
| 125 |
NCT00215735 |
Terminated |
Effect of Platelet Concentrate in Treatment of Diabetic Ulcers |
|
- Device: debridement, dressing, and APC
|
Interventional |
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00215735 |
2003-1 |
|
June 2004 |
September 2005 |
September 2005 |
September 22, 2005 |
March 20, 2012 |
|
- Washington Regional Medical Center
Fayetteville, Alaska, United States - Lucerne Hospital
Orlando, Florida, United States - Bay Pines V.A. Medical Center
St. Petersburg, Florida, United States - (and 6 more...)
|
| 126 |
NCT00050089 |
Completed
Has Results |
CSP #512 - Options in Management With Anti-Retrovirals |
|
- Other: No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP
- Drug: Standard ART vs Mega ART
|
Interventional |
Not Applicable |
- VA Office of Research and Development
- Medical Research Council
- Canadian Institutes of Health Research (CIHR)
|
U.S. Fed / Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With New or Recurrent AIDS Event, or Death
- Number of Participants With a New, Non-HIV Related Serious Adverse Event
- Number of Participants With New, Non-HIV Related Serious Adverse Event
|
368 |
All |
18 Years and older (Adult, Senior) |
NCT00050089 |
512 |
OPTIMA |
January 2001 |
December 2007 |
December 2007 |
November 22, 2002 |
April 23, 2015 |
February 13, 2014 |
- Carl T. Hayden VA Medical Center
Phoenix, Arizona, United States - VA Medical Center, Long Beach
Long Beach, California, United States - VA Palo Alto Health Care System
Palo Alto, California, United States - (and 27 more...)
|
| 127 |
NCT00106821 |
Completed |
Efficacy of Tiotropium in Patients of African Descent With Chronic Obstructive Pulmonary Disease |
- Pulmonary Disease, Chronic Obstructive
|
- Drug: Tiotropium Bromide Inhalation Powder
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- The primary efficacy endpoint will be FEV1 AUC (0-3) after 8 weeks of treatment
- FEV1 AUC0-3 after single dose, 4 weeks of treatment, peak FEV1 on each test day, trough FEV1 at weeks 4 & 8, FVC trough (weeks 4 & 8), peak and AUC(0-3) (on all test days), FEV1 and FVC at all time points, rescue albuterol use, dyspnea SOP questionnaire
|
166 |
All |
40 Years and older (Adult, Senior) |
NCT00106821 |
205.294 |
|
June 2004 |
August 2005 |
|
April 1, 2005 |
November 1, 2013 |
|
- Boehringer Ingelheim Investigational Site
Birmingham, Alabama, United States - Cooper Green Hospital
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - (and 16 more...)
|
Create an RSS feed from your search for:
Download the search results for: